Scarica l'app Stockscreener
3.15
1.56%
-0.05
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Galectin Therapeutics Inc Borsa (GALT) Ultime notizie
Will Galectin Therapeutics Inc. stock continue dividend increasesJuly 2025 Closing Moves & Detailed Earnings Play Strategies - ulpravda.ru
Galectin Therapeutics Inc.'s (NASDAQ:GALT) Last Week's 23% Decline Must Have Disappointed Individual Investors Who Have a Significant Stake - 富途牛牛
Can Galectin Therapeutics Inc. (PHPN) stock sustain institutional flowsJuly 2025 Drop Watch & AI Enhanced Execution Alerts - ulpravda.ru
Is Galectin Therapeutics Inc. (PHPN) stock a safe buy pre earningsJuly 2025 Spike Watch & Fast Gain Swing Trade Alerts - ulpravda.ru
Will Galectin Therapeutics Inc. stock benefit from automationJuly 2025 Trade Ideas & High Accuracy Investment Entry Signals - ulpravda.ru
Fraud Investigation Opened: Levi & Korsinsky Investigates Galectin Therapeutics Inc. (GALT) on Behalf of Shareholders - ACCESS Newswire
Is Galectin Therapeutics Inc. stock resilient to inflationJuly 2025 Review & Precise Swing Trade Entry Alerts - ulpravda.ru
How buybacks impact Galectin Therapeutics Inc. stock value2025 Momentum Check & Consistent Return Strategy Ideas - ulpravda.ru
Is Galectin Therapeutics Inc. stock attractive for income investors2025 Growth vs Value & High Win Rate Trade Tips - ulpravda.ru
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc.GALT - Chartmill
Institution Moves: Will Galectin Therapeutics Inc. (PHPN) stock beat Nasdaq index returnsJuly 2025 Earnings & Safe Investment Capital Preservation Plans - ulpravda.ru
Market Trends: Will Galectin Therapeutics Inc PHPN stock beat Nasdaq index returnsJuly 2025 Retail & Real-Time Volume Analysis Alerts - moha.gov.vn
GALT Investors Have Opportunity to Join Galectin Therapeutics Inc. Fraud Investigation with the Schall Law Firm - GlobeNewswire
Galectin Therapeutics CFO sells $233k in shares By Investing.com - Investing.com Nigeria
Galectin Therapeutics CFO sells $233k in shares - Investing.com
Insider Sell: Jack Callicutt Sells 60,000 Shares of Galectin The - GuruFocus
Khurram Jamil Sells 21,446 Shares of Galectin Therapeutics (NASDAQ:GALT) Stock - MarketBeat
Galectin Therapeutics (NASDAQ:GALT) CFO Sells $58,438.80 in Stock - MarketBeat
Insider Selling: Galectin Therapeutics (NASDAQ:GALT) CEO Sells 18,571 Shares of Stock - MarketBeat
Joel Lewis Sells 27,731 Shares of Galectin Therapeutics (NASDAQ:GALT) Stock - MarketBeat
Galectin Therapeutics (NASDAQ:GALT) Insider Khurram Jamil Sells 13,055 Shares - MarketBeat
Insider Selling: Galectin Therapeutics (NASDAQ:GALT) CFO Sells 20,354 Shares of Stock - MarketBeat
Galectin Therapeutics Faces Securities Fraud Investigation as Stock Plummets 28.9% - Intellectia AI
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin ... - Bluefield Daily Telegraph
Should I hold or sell Galectin Therapeutics Inc. stock in 20252026 world cup usa national team qualification top scorers build up play knockout prediction preview - ulpravda.ru
Galectin Therapeutics Inc. (GALT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Galectin Therapeutics reveals promising NAVIGATE trial results - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Galectin Therapeutics Inc. (GALT) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Inflation Data: Why Galectin Therapeutics Inc stock could rally in 2025Market Movers & Reliable Breakout Forecasts - moha.gov.vn
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors ofGALT - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Galectin Therapeutics Inc. (GALT) Investors to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Galectin Therapeutics Inc. (GALT) And Encourages Investors to Reach Out - ACCESS Newswire
Galectin Therapeutics Shares Plunge 28.9% Following FDA Response on Belapectin Development - Intellectia AI
GALT Investors Have Opportunity to Join Galectin Therapeutics Inc. Fraud Investigation with The Schall Law Firm - The AI Journal
Galectin Therapeutics: Runway With Convertible Financing But Dilution Overhang Remains - Seeking Alpha
Freeman Kevin D, director at Galectin Therapeutics, buys $19,514 in shares - Investing.com Australia
Eldred Kary, director at Galectin Therapeutics, buys $2611 in stock By Investing.com - Investing.com Nigeria
Eldred Kary, Galectin Therapeutics director, buys $2.6k in shares By Investing.com - Investing.com South Africa
Freeman Kevin D, director at Galectin Therapeutics, buys $19,514 in shares By Investing.com - Investing.com South Africa
Galectin therapeutics director Kevin Freeman buys $19,514 in stock By Investing.com - Investing.com Canada
Galectin therapeutics director Kevin Freeman buys $19,514 in stock - Investing.com
Eldred Kary, Galectin Therapeutics director, buys $2.6k in shares - Investing.com
Freeman buys Galectin Therapeutics (GALT) shares worth $19,514 By Investing.com - Investing.com Nigeria
Eldred Kary, director at Galectin Therapeutics, buys $2611 in stock - Investing.com
Freeman buys Galectin Therapeutics (GALT) shares worth $19,514 - Investing.com India
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):